NST002 Phase IIa Study (ALS) Promising Results Continue Reports NeuroSense
The study is set to be completed in January of 2021, following 12-months dosing.
Request Advertising / Posting Opportunities
Copyright © 2025 Medical Device News Magazine, a division of PTM Healthcare Marketing, Inc. All Rights Reserved
Hours:
M – F 8 am – 5 pm
Florida / New York
Phone: 561.316.3330